Real life experience and predictors of visual outcomes with intravitreal brolucizumab switch for treatment of neovascular age-related macular degeneration
Introduction: To analyze visual and anatomical outcomes after switching to intravitreal brolucizumab therapy in eyes affected by neovascular age-related macular degeneration (nAMD) previously treated with other intravitreal anti-vascular endothelial growth factor (VEGF) agents.
Methods: Retrospective study of eyes with nAMD who underwent intravitreal brolucizumab at San Raffaele Hospital (Milan, Italy) or San Rocco Clinical Institute (Ome, Italy) between January 2021 and July 2022. All study eyes had persistent residual retinal fluid after receiving at least 3 intravitreal injections of other anti-VEGF agents prior to swi...
Source: Ophthalmologica - April 11, 2023 Category: Opthalmology Source Type: research
Influence of surgical experience and risk factors for surgical failure in primary retinal detachment surgery
Introduction: The aim of this study was to report surgical outcomes and risk factors for primary surgical failure following rhegmatogenous retinal detachment (RRD) repair
Methods: In this retrospective cohort study, RRD patients who underwent primary surgery at a tertiary center between January 1, 2006 and December 31, 2020 were enrolled. Surgical failure was defined as reoperation within 60 days postoperatively due to retinal re-detachment and putative risk factors for surgical failure were analyzed.
Results: Of 2383 eyes (2335 patients), 1342 (56.3%) underwent vitrectomy, and 1041 (43.7%) underwent scleral buckling. Th...
Source: Ophthalmologica - April 6, 2023 Category: Opthalmology Source Type: research
Associations and Prognostic Significance of Fluctuations in Diabetic Retinopathy Severity in Eyes Treated for Diabetic Macular Edema
Conclusion: Patients with larger DR variability in response to intravitreal injections may be at higher risk of DR progression. We advocate attentive follow-up in these patients to recognize PDR early. (Source: Ophthalmologica)
Source: Ophthalmologica - March 30, 2023 Category: Opthalmology Source Type: research
Maximal Extension Interval and Visual Outcomes in a Treat-and-Extend Protocol: A Post Hoc Analysis of the CANTREAT Randomized Trial
Conclusion: The capacity to extend does not necessarily associate with improved visual acuity outcomes, with the poorest change in BCVA seen in those extended 8 –10 weeks. The highest change in BCVA and lowest decrease in CRT was in the group maximally extended for 4 weeks. There was a correlation between change in BCVA and change in CRT for other extension groups. Future studies should establish the predictive factors for successful extension in patients undergoing Tamp;E in nAMD. (Source: Ophthalmologica)
Source: Ophthalmologica - March 27, 2023 Category: Opthalmology Source Type: research
Maximal Extension Interval and Visual Outcomes in a Treat-and-Extend Protocol: A Post-Hoc Analysis of the CANTREAT Randomized Trial
Conclusion: The capacity to extend does not necessarily associate with improved visual acuity outcomes, with the poorest change in BCVA see n in those extended 8-10 weeks. The highest change in BCVA and lowest decrease in CRT was in the group maximally extended for 4 weeks. There was a correlation between change in BCVA and change in CRT for other extension groups. Future studies should establish the predictive factors for successful ex tension in patients undergoing TE in nAMD. (Source: Ophthalmologica)
Source: Ophthalmologica - March 27, 2023 Category: Opthalmology Source Type: research
Brolucizumab For Wet Age-Related Macular Degeneration: One-Year Real-World Experience From A Tertiary Center
Introduction
To explore the early efficacy and safety of treatment with intravitreal injections of brolucizumab in patients presenting neovascular age-related macular degeneration (nAMD) in a real-world setting.
Methods
This retrospective study included 194 eyes of 180 patients with nAMD treated with standard 6-mg intravitreal injections (IVTs) of brolucizumab in our clinic between 11 March 2021 and 15 June 2022. Both treatment-naive (33 eyes) and switch-therapy patients (161 eyes) were included in the study. Best corrected visual acuity (BCVA), central subfield thickness (CST), retinal fluid distribution (classified as...
Source: Ophthalmologica - February 24, 2023 Category: Opthalmology Source Type: research
Erratum
Ophthalmologica (Source: Ophthalmologica)
Source: Ophthalmologica - February 22, 2023 Category: Opthalmology Source Type: research
Clinical Presentations, Management, and Factors Affecting Outcomes in Posterior Segment Open Globe Injuries: An Analysis of 2,360 Eyes
Conclusions: In the absence of retinal detachment and orbital fracture, posterior open globe injuries typically have a favorable functional outcome. OTS correlated with the final visual acuity. (Source: Ophthalmologica)
Source: Ophthalmologica - February 20, 2023 Category: Opthalmology Source Type: research
Clinical presentations, management and factors affecting outcomes in posterior segment open globe injuries – An analysis of 2360 eyes
Conclusions
In the absence of retinal detachment and orbital fracture, posterior open globe injuries typically have a favorable functional outcome. OTS correlated with the final visual acuity. (Source: Ophthalmologica)
Source: Ophthalmologica - February 20, 2023 Category: Opthalmology Source Type: research
Associations with non-persistence with intra-vitreal therapy for neovascular age-related macular degeneration at 24 months
Conclusions: Non-persistence with treatment was common, especially in the first year of treatment, and was often associated with a decrease in visual acuity. Treatment site, baseline visual acuity and age were the strongest predictors of treatment non-persistence before day 720. U nderstanding and addressing reasons for non-persistence are important to ensure that effective but expensive treatments are used cost-effectively and to maintain acuity. Variation in non-persistence between sites, even after adjustment for other variables, suggests that local factors in treatment pr ovision may be particularly important. (Source: Ophthalmologica)
Source: Ophthalmologica - February 6, 2023 Category: Opthalmology Source Type: research
Short-term safety and efficacy of intravitreal brolucizumab injections for neovascular age-related macular degeneration: a multicenter retrospective real-world study
Conclusion: IOI was well-controlled with or without steroid treatment. Most IOI eyes (95.1%) were restored to the level of vision before IOI occurrence and occlusive vasculitis was rare. In the short term, brolucizumab injection effectively improved vision at 1 month and dried ret inal fluid for 3 months. (Source: Ophthalmologica)
Source: Ophthalmologica - January 31, 2023 Category: Opthalmology Source Type: research
The effects of treatment regimen on the initial management of macular neovascularization subtypes in age-related macular degeneration
CONCLUSION: The individualization of the initial treatment protocol according to MNV subtype can improve the functional outcome and may decrease the treatment burden. (Source: Ophthalmologica)
Source: Ophthalmologica - January 31, 2023 Category: Opthalmology Source Type: research
Changes in serum concentrations of vascular endothelial growth factors-A and B after intravitreal injection of ranibizumab and conbercept for retinopathy of prematurity
Introduction To compare the changes in serum concentrations of vascular endothelial growth factor (VEGF)-A and B after intravitreal injection of ranibizumab (IVR) or conbercept (IVC) for retinopathy of prematurity (ROP). Methods In this prospective study, infants with type 1 ROP in both eyes were recruited in our hospital from September 2021 to February 2022, randomly assigned to the ranibizumab and conbercept groups and administered IVR or IVC (0.25 mg/0.025 mL). Blood samples were collected before the operation and 1 and 4 weeks after the operation to measure the concentrations of serum VEGF-A and B. Results A total of 2...
Source: Ophthalmologica - January 27, 2023 Category: Opthalmology Source Type: research
Contents
Ophthalmologica 2022;245:I –VI (Source: Ophthalmologica)
Source: Ophthalmologica - January 26, 2023 Category: Opthalmology Source Type: research
Acknowledgement to Reviewers
Ophthalmologica 2022;245:592 –593 (Source: Ophthalmologica)
Source: Ophthalmologica - January 26, 2023 Category: Opthalmology Source Type: research
